Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Work In Process: 2021-2023

Historic Work In Process for Apellis Pharmaceuticals (APLS) over the last 3 years, with Dec 2023 value amounting to $82.9 million.

  • Apellis Pharmaceuticals' Work In Process rose 119.02% to $106.2 million in Q1 2024 from the same period last year, while for Mar 2024 it was $106.2 million, marking a year-over-year increase of 119.02%. This contributed to the annual value of $82.9 million for FY2023, which is 53.28% up from last year.
  • As of FY2023, Apellis Pharmaceuticals' Work In Process stood at $82.9 million, which was up 53.28% from $54.1 million recorded in FY2022.
  • Apellis Pharmaceuticals' 5-year Work In Process high stood at $82.9 million for FY2023, and its period low was $10.1 million during FY2021.
  • Its 3-year average for Work In Process is $49.0 million, with a median of $54.1 million in 2022.
  • Data for Apellis Pharmaceuticals' Work In Process shows a peak YoY surged of 437.89% (in 2022) over the last 5 years.
  • Apellis Pharmaceuticals' Work In Process (Yearly) stood at $10.1 million in 2021, then surged by 437.89% to $54.1 million in 2022, then spiked by 53.28% to $82.9 million in 2023.